Diffusion Pharmaceuticals (DFFN) Sees Unusually-High Trading Volume

Share on StockTwits

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) saw unusually-high trading volume on Wednesday . Approximately 1,456,233 shares changed hands during trading, an increase of 612% from the previous session’s volume of 204,515 shares.The stock last traded at $6.00 and had previously closed at $4.87.

DFFN has been the topic of a number of recent research reports. ValuEngine lowered shares of Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 2nd. HC Wainwright set a $15.00 price target on shares of Diffusion Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 15th.

The stock has a market capitalization of $18.03 million, a P/E ratio of -0.28 and a beta of 0.27.

An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned approximately 0.95% of Diffusion Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.24% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Diffusion Pharmaceuticals (DFFN) Sees Unusually-High Trading Volume” was originally published by Zolmax and is owned by of Zolmax. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://zolmax.com/investing/diffusion-pharmaceuticals-dffn-sees-unusually-high-trading-volume/2966295.html.

Diffusion Pharmaceuticals Company Profile (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Featured Article: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Diffusion Pharmaceuticals  Sees Unusually-High Trading Volume
Diffusion Pharmaceuticals Sees Unusually-High Trading Volume
U.S. Global Investors  vs. Federated Investors  Head to Head Analysis
U.S. Global Investors vs. Federated Investors Head to Head Analysis
BTB Real Estate Investment Trust  Price Target Raised to C$4.65
BTB Real Estate Investment Trust Price Target Raised to C$4.65
CGI  Price Target Increased to C$92.00 by Analysts at CIBC
CGI Price Target Increased to C$92.00 by Analysts at CIBC
BMO Capital Markets Reiterates Outperform Rating for Interfor
BMO Capital Markets Reiterates Outperform Rating for Interfor
Canadian Natural Resources  Price Target Increased to C$50.00 by Analysts at CSFB
Canadian Natural Resources Price Target Increased to C$50.00 by Analysts at CSFB


Leave a Reply

 
© 2006-2019 Zolmax.